West of Scotland Cancer Network

Urological Cancer Managed Clinical Network



Audit Report

Renal Pelvis and Ureter Cancers Key Outcome Measures

Clinical Audit Data 2017

Mr Gren Oades

MCN Clinical Lead

Tom Kane MCN Manager

David New Information Officer

The content of this report is © copyright WoSCAN unless otherwise stated.

Introduction

This report contains an assessment of the performance of West of Scotland (WoS) urological cancer services using clinical audit data relating to patients diagnosed with renal pelvis and ureter (RPU) cancers in Year 6. In 2011, a core review group initiated by the West of Scotland Cancer Network (WoSCAN) developed key outcome measures (KOMs) for patients diagnosed with RPU cancer and five years of data from 2013 to 2017 (Years 2 – 6) are presented within this report.

Methodology


The clinical audit data presented in this report was collected by clinical audit staff in each NHS Board in accordance with an agreed dataset and definitions. The data was entered locally into the electronic Cancer Audit Support Environment (eCASE): a secure centralised web-based database. Data relating to patients diagnosed between 1st January 2017 and 31st December 2017 was downloaded from eCASE on 14th November 2018.

Analysis was performed centrally by the WoSCAN Information Team and the timescales agreed took into account the patient pathway to ensure that a complete treatment record was available for each case. Initial results of the analysis were provided to local Boards to check for inaccuracies or obvious gaps before final analysis was carried out. Final results were disseminated for NHS Board verification in line with the regional audit governance process, to ensure that the data was an accurate representation of service in each area.

Background


There were 99 new diagnoses of RPU cancer captured by audit in the WoS in Year 6. Distribution by location of diagnosis is shown below in Figure 1. The ratio of male to female cases is 1.2:1 with 54 men and 45 women diagnosed with RPU cancer in 2017. The age distribution differs between the sexes, as illustrated in Figure 2; however the greatest frequency of new diagnoses occurs between the ages of 70 to 74 years for men and between 80 to 84 years for women.

Figure 1: Proportion of patients in WoS diagnosed with RPU cancer by NHS Board of diagnosis in 2017.



	AA	FV	GGC	Lan	WoS
N	10	17	58	14	99
%	10.1%	17.2%	58.6%	14.1%	-

Figure 2: Number of patients diagnosed with RPU cancer in 2017 in WoS by age group and sex.



Age group (years)

	<45	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	>85
Male	1	0	1	2	5	7	16	11	9	2
Female	0	0	2	2	4	9	5	6	14	3

The majority of people diagnosed with RPU cancers are in the older age groups with two thirds of cases (66/99, 66.7%) in 2017 occurring in people aged 70 years and over at the time of diagnosis. The median age at diagnosis was 73 years for men and 76 years for women.


Key Outcome Measures

Patients Discussed at Multidisciplinary Team (MDT) Meeting

As with all other urological cancers, patients diagnosed with RPU cancers are discussed and managed by multidisciplinary teams (MDTs). The configuration of urological cancer MDTs in the region is set out below and each MDT convenes on a weekly basis.

MDT	Constituent Hospitals			
Ayrshire & Arran (AA)	Crosshouse Hospital, Ayr Hospital			
	(i) Glasgow Royal Infirmary, Stobhill Hospital			
Pan Glasgow	(ii) Queen Elizabeth University Hospital, Victoria Infirmary, Gartnavel			
	General Hospital			
Clyde	Royal Alexandria Hospital, Inverclyde Royal Hospital, Vale of Leven			
Forth Valley (FV)	Forth Valley Royal Hospital			
Lanarkshire (Lan)	Monklands District General, Wishaw General Hospital, Hairmyres Hospital			

Figure 3: Proportion of patients diagnosed with RPU cancer discussed at MDT by NHS Board, 2013 - 2017.




	Performance (%)	Numerator	Denominator
AA	100.0%	10	10
FV	88.2%	15	17
GGC	98.3%	57	58
Lan	100.0%	14	14
WoSCAN	97.0%	96	99

Of the 99 cases of RPU cancer in the WoS in 2017, 96 were discussed at MDT giving a performance of 97.0%. Board performance ranged from 88.2% for NHS Forth Valley to 100.0% for NHS Ayrshire and Arran and NHS Lanarkshire. The performance is slightly down compared to last year although performances have remained consistent over the 5 years shown.

Clinical TNM

Staging of patients at diagnosis aids treatment decision making and can be an indicator of prognosis.

Figure 4: Proportion of patients diagnosed with RPU cancer with TNM recorded by NHS Board, 2013 - 2017.



	Performance (%)	Numerator	Denominator
AA	100.0%	10	10
FV	94.1%	16	17
GGC	100.0%	58	58
Lan	100.0%	14	14
WoSCAN	99.0%	98	99

The overall performance for the WoS was 99.0% in 2017 which shows significant improvement compared to 2016 (76.0%). In 2017, all Boards showed improvement on Year 5 performance.

Surgeons Performing Nephroureterectomy

There is a relationship between improved surgical outcomes and volume of cases performed. The number of nephroureterectomies performed by surgeons in the WoS is shown below. This includes all patients who had a nephroureterectomy in 2017 and not just those diagnosed in that year.

Figure 5 shows the number of procedures performed by each NHS Board within the WoS. 45.5% of nephroureterectomies were performed within NHS Greater Glasgow and Clyde.

Figure 5: Proportion of nephroureterectomies performed in the WoS, by NHS Board 2015 - 2017.

	2015		20	16	2017		
	N	%	N	%	Ν	%	
Ayrshire and							
Arran	1	3.3%	8	21.1%	4	9.1%	
Forth Valley	4	13.3%	6	15.8%	7	15.9%	
Greater Glasgow and Clyde	13	43.3%	17	44.7%	20	45.5%	
Lanarkshire	12	40.0%	7	18.4%	8	18.2%	
WoS	30	-	38	-	44	-	

Figure 6 shows the number of procedures performed by individual surgeons within each NHS Board in the WoS.

Figure 6: Number of nephroureterectomies performed by surgeons in the WoS, by NHS Board in 2017.

	ire and ran	Forth Valley	Gre	ater Gl	asgow an	d Clyde	Lanarks	shire	Not Recorded	WoS
Α	В	С	D	Е	F	G	Н	I	-	Total
3	1	7	1	3	6	10	7	1	5	44

Action:

• NHS Ayrshire and Arran, NHS Greater Glasgow and Clyde and NHS Lanarkshire to provide feedback where a surgeon has performed a single surgical case.

Thirty-day mortality following nephroureterectomy

Treatment related mortality is a marker of the quality and safety of the whole service provided by the Multi Disciplinary Team (MDT). This KOM is intended to ensure treatment is given appropriately.

There were 46 nephroureterectomy procedures carried out across WoS NHS Boards for patients diagnosed in 2017. 46.5% (46/99) of patients diagnosed with RPU cancer in 2017 had a nephroureterectomy performed. There was one death (2.2%) within 30 days of nephroureterectomy in the WoS. The highest WoS mortality rate was 3.7% in 2015.

	2015				2016		2017		
	N	D	%	N	D	%	N	D	%
AA	-	-	-	0	7	0.0%	0	5	0.0%
FV	-	-	-	0	6	0.0%	0	6	0.0%
GGC	0	13	0.0%	0	16	0.0%	1	27	3.7%
Lan	1	7	14.3%	0	6	0.0%	0	8	0.0%
WoS	1	27	3.7%	0	35	0.0%	1	46	2.2%

Conclusion

Cancer audit data underpins much of the regional development and service improvement work of the MCN and regular reporting of activity and performance is a fundamental requirement of an MCN to assure the quality of care delivered across the region.

The recording of TNM data is fundamental in aiding treatment decision making for patients diagnosed with RPU cancers and significant improvements have been noted for all Boards in Year 6. Performance with regards to MDT discussion and 30-day mortality following nephroureterectomy is of a high standard.

The MCN will actively take forward regional actions identified and NHS Boards are asked to develop local Action/Improvement Plans in response to the findings presented in the report. A summary of actions for each NHS Board has been included within the Action Plan templates in the Appendix.

Actions required:

Surgeons Performing Nephroureterectomy

• NHS Ayrshire and Arran, NHS Greater Glasgow and Clyde and NHS Lanarkshire to provide feedback where a surgeon has performed a single surgical case.

Completed Action Plans should be returned to WoSCAN within two months of publication of this report.

Progress against these plans will be monitored by the MCN Steering Group and any service or clinical issue which the Steering Group considers not to have been adequately addressed will be escalated to the NHS Board Territorial Lead Cancer Clinician and Regional Lead Cancer Clinician.

Additionally, progress will be reported to the Regional Cancer Advisory Group (RCAG) annually by NHS Board Territorial Lead Cancer Clinicians and MCN Clinical Leads, as part of the regional audit governance process to enable RCAG to review and monitor regional improvement.

Acknowledgement

This report has been prepared using clinical audit data provided by the following NHS Boards in the WoSCAN area:

NHS Ayrshire & Arran NHS Forth Valley NHS Greater Glasgow and Clyde NHS Lanarkshire

We would like to thank all members and active participants in the cancer network for their continued support of the MCN, and the many hospitals that are committed to making the audit succeed. We also acknowledge the efforts of the clinical effectiveness staff, nurses, and other service users for their work in ensuring the data are available to enable analysis to take place each year. Without their considerable efforts this level of progress would not be possible.

Abbreviations

AA	NHS Ayrshire & Arran
e-CASE	Electronic Cancer Audit Support Environment
FV	Forth Valley
GGC	NHS Greater Glasgow and Clyde
KOM(s)	Key Outcome Measure(s)
Lan	Lanarkshire
MCN	Managed Clinical Network
MDT	Multidisciplinary Team
NHSGGC	NHS Greater Glasgow and Clyde
RCAG	Regional Cancer Advisory Group
RPU	Renal pelvis & ureter
TNM	Tumour, Nodes, Metastases (staging system)
WoS	West of Scotland
WoSCAN	West of Scotland Cancer Network

Copyright

The content of this report is © copyright WoSCAN unless otherwise stated.

Organisations may copy, quote, publish and broadcast material from this report without payment and without approval provided they observe the conditions below. Other users may copy or download material for private research and study without payment and without approval provided they observe the conditions below.

The conditions of the waiver of copyright are that users observe the following conditions:

- Quote the source as the West of Scotland Cancer Network (WoSCAN).
- Do not use the material in a misleading context or in a derogatory manner.
- Where possible, send us the URL.

The following material may not be copied and is excluded from the waiver:

- The West of Scotland Cancer Network logo.
- Any photographs.

Any other use of copyright material belonging to the West of Scotland Cancer Network requires the formal permission of the Network.

Appendix: NHS Board Action Plans RPU KOMs

A summary of actions for each NHS Board has been included within the following Action Plan templates. Completed Action Plans should be returned to WoSCAN within two months of publication of this report.

RPU Action / Improvement Plan

Area:	NHS Ayrshire and Arran
Action Plan Lead:	
Date:	

KEY (Status)					
1	Action fully implemented				
2	Action agreed but not yet implemented				
3	No action taken (please state reason)				

KOM	Action Poquired	Health Board Action	Timescales		Lood	Progress/Action Status	Status
KOIVI	Action Required	Taken	Start	End	Lead	Progress/Action Status	(see Key)
	Ensure actions mirror those detailed in Audit Report.	Detail specific actions that will be taken by the NHS Board.	Insert date	Insert date	Insert name of responsible lead for each specific action.	Provide detail of action in progress, change in practices, problems encountered or reasons why no action taken.	Insert No. from key above.
Surgeons Performing Nephroureterectomy	Provide feedback where a surgeon has performed a single surgical case.						

RPU Action / Improvement Plan

Area:	NHS Greater Glasgow and Clyde					
Action Plan Lead:						
Date:						

KEY (Status)			
1	Action fully implemented		
2	Action agreed but not yet implemented		
3	No action taken (please state reason)		

ком	Action Required	Health Board Action Taken	Timescales		Lood	Dragrace/Action Status	Status
			Start	End	Lead	Progress/Action Status	(see Key)
	Ensure actions mirror those detailed in Audit Report.	Detail specific actions that will be taken by the NHS Board.	Insert date	Insert date	Insert name of responsible lead for each specific action.	Provide detail of action in progress, change in practices, problems encountered or reasons why no action taken.	Insert No. from key above.
Surgeons Performing Nephroureterectomy	Provide feedback where a surgeon has performed a single surgical case.						

RPU Action / Improvement Plan

Area:	NHS Lanarkshire				
Action Plan Lead:					
Date:					

KEY (Status)			
1	Action fully implemented		
2	Action agreed but not yet implemented		
3	No action taken (please state reason)		

ком	Action Required	Health Board Action Taken	Timescales		Lood	Drogram / Action Status	Status
			Start	End	Lead	Progress/Action Status	(see Key)
	Ensure actions mirror those detailed in Audit Report.	Detail specific actions that will be taken by the NHS Board.	Insert date	Insert date	Insert name of responsible lead for each specific action.	Provide detail of action in progress, change in practices, problems encountered or reasons why no action taken.	Insert No. from key above.
Surgeons Performing Nephroureterectomy	Provide feedback where a surgeon has performed a single surgical case.						